Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.
about
Checkpoint Inhibitors and Their Application in Breast CancerTumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune TargetingInterplay between Cellular and Molecular Inflammatory Mediators in Lung CancerClinical Significance of Programmed Death Ligand‑1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma.Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancerIndependent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma.Mechanism of immune evasion in breast cancer.Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility.Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer.PD-L1 and intratumoral immune response in breast cancer.Identification of candidate genes associated with triple negative breast cancer.Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis.Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients.PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?First international TNBC conference meeting report.Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going.Prognostic value of PD -L1 expression in patients with primary solid tumors.PD1 protein expression in tumor infiltrated lymphocytes rather than PDL1 in tumor cells predicts survival in triple-negative breast cancer.MUC1-C Induces PD-L1 and Immune Evasion in Triple-Negative Breast Cancer.Expression and Clinical Significance of Claudin-7, PDL-1, PTEN, c-Kit, c-Met, c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in Triple-negative Breast Cancer-A Single Centre Prospective Observational Study.The Role of Immune Escape and Immune Cell Infiltration in Breast CancerDiagnostic value of PD-1 mRNA expression combined with breast ultrasound in breast cancer patients
P2860
Q26745442-90171ABC-C690-4943-8FEB-5071F56FFED3Q26747792-14B32B75-33DF-4809-9E7F-F9B3AA0358ACQ26768652-C426C20E-593A-4397-A1D7-E329BF5ED651Q36261405-021ED663-2EE1-47CC-BFC2-CB2E319F0B37Q36994508-EB7A440E-39F3-4F1B-B319-6E04FCD85BE8Q37702580-A7FFA339-3B1A-4006-9A52-FA08770003C2Q37702705-9C3D26FA-10BA-4C37-AFFC-5405D3B3EA1CQ37712385-6940D5B4-5B3B-4299-9AC9-260160FCB7E2Q38629357-4E87332E-590F-4338-8621-957079F55507Q38704949-FED8F75D-6291-408E-8E73-C18B0B2158C7Q38734804-2D27DF58-5E9A-47F0-BBA6-F08501498D34Q40560246-D4778244-B0DB-40DD-AA02-1A63FAF0DAA9Q41612935-11BD5166-BF15-4E4F-A1E8-DA65890BAABCQ41659323-6256C5D5-60B6-4540-93B6-FEADEF78065DQ42504152-FD342053-59B5-4082-949C-647695929A49Q42700308-1E2FE350-250E-4B51-90E7-7CC88CD3E7C8Q47125869-71BF9A20-EC88-4AD4-8B54-135DE37AF33CQ48008350-503E03A5-D88D-4334-91ED-15505FA69641Q48128973-146210F0-3AF0-496D-A7EC-D3991EA2BBC6Q48502628-35B85FA6-4E9E-4E56-86C3-FB80B22AE6F9Q49303842-368BF0D6-9853-4C64-9D51-C645D87DECDEQ49732572-8BA9D7A0-D297-470B-AC77-03C20B2E7D12Q50035044-F00C5D5B-1F1A-4AF3-916F-AD2FA8F5F436Q52742033-8356C062-5B78-4AF3-8971-CDEF7A844CBEQ55278765-33EFA4BE-6314-45AA-88CD-82D0826C9EABQ57114285-EA29AEDD-84C9-43F1-85A8-B4AE71D146C3Q58698521-AE7569AD-1543-4A6B-B4C1-3232D6D85596
P2860
Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Programmed death ligand 1 expr ...... phocytes and improved outcome.
@en
type
label
Programmed death ligand 1 expr ...... phocytes and improved outcome.
@en
prefLabel
Programmed death ligand 1 expr ...... phocytes and improved outcome.
@en
P2093
P2860
P50
P356
P1433
P1476
Programmed death ligand 1 expr ...... mphocytes and improved outcome
@en
P2093
Anna McLean
Anne Holliday
Caroline L Cooper
Catherine W Kennedy
Catriona M McNeil
Charles Chan
Christina I Selinger
David Gillett
Elizabeth Robbins
P2860
P356
10.1111/HIS.12904
P577
2016-01-13T00:00:00Z